SCHEMBL24324875

SCHEMBL24324875

C=C(C)Nc1ccc(CC(C)C(C)C)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 3/20 0.41
KMT2A Q03164 5/20 0.39
ALOX15 P16050 4/20 0.39
ALOX12 P18054 4/20 0.39
MEN1 O00255 4/20 0.39
ALDH1A1 P00352 3/20 0.39
MAPK1 P28482 3/20 0.39
KDM4E B2RXH2 2/20 0.39
ESR1 P03372 2/20 0.39
TP53 P04637 2/20 0.39
CYP3A4 P08684 2/20 0.39
HPGD P15428 2/20 0.39
RECQL P46063 2/20 0.39
HIF1A Q16665 2/20 0.39
HSD17B10 Q99714 2/20 0.39
MAPT P10636 2/20 0.39
RAB9A P51151 2/20 0.39
NR3C1 P04150 2/20 0.39
FOS P01100 2/20 0.39
TTR P02766 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19889897 0.85 SMN1; SMN2 (0.50) KMT2AMEN1ALDH1A1MAPK1ESR1
SCHEMBL22281922 0.78 KMT2A (0.49) KMT2AMEN1MAPK1ESR1MAPT
SCHEMBL19825999 0.76 SMN1; SMN2 (0.46) KMT2AMEN1ALDH1A1KDM4ECYP3A4
SCHEMBL21386360 0.75 SRC (0.52) KMT2AALOX15ALOX12MEN1ALDH1A1
SCHEMBL17244567 0.73 SMYD3 (0.45)
SCHEMBL23350825 0.72 RAB9A (0.40) KMT2AMEN1ALDH1A1MAPK1MAPT
SCHEMBL29310011 0.72 POLB (0.49) ALDH1A1HPGDRAB9ALMNAPOLB
SCHEMBL18715977 0.71 PTPRF (0.49) KMT2APPARGFPR2
SCHEMBL12190501 0.71 KIF11 (0.52) KMT2AALOX12MEN1ALDH1A1KDM4E
SCHEMBL13536799 0.70 GAA (0.46) KMT2AMEN1ALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220112242-A1 SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME CDRD VENTURES INC. (CA) 2022-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220112242-A1 SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME GPR119, SSTR5, SSTR2 TRPA1 1786/4885KMT2A 3970/4885ALOX15 2333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.